Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Stakeholder Insight - Chronic Leukemias - Is there room left for improvement? (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 24/11/2008
- Report Title: Stakeholder Insight - Chronic Leukemias - Is there room left for improvement?
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 362
Introduction
CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.
Scope
*Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key opinion leaders
*Segmentation of CLL and CML population by disease stage at presentation and proportion receiving anti-cancer therapy
*In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for CLL and CML by line of therapy and disease stage
*Ranking of key prescribing influences in CLL and CML, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview
Highlights
Rituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo) has received considerable off-label use for chronic lymphocytic leukemia (CLL), particularly in the US. Positive Phase III data are likely to drive increased uptake in the EU. Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering).
Gleevec is firmly established as the standard-of-care for newly diagnosed chronic phase CML, while the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) are experiencing increasing uptake in Gleevec-resistant and accelerated phase patients.
Sprycel currently commands a higher market share than Tasigna for CML, benefiting from its first-to-market advantage. However, physicians' perceptions of Sprycel and Tasigna show little differentiation, and there will be close competition for market share in the coming years.
Reasons to Purchase
*Understand prescribing trends and identify key factors that influence treatment choices in CLL and CML
*Examine unmet need within the CLL and CML markets and identify opportunities for new product development
*Enhance commercial positioning by increasing understanding of current dynamics within the CLL and CML markets
CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.
Scope
*Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key opinion leaders
*Segmentation of CLL and CML population by disease stage at presentation and proportion receiving anti-cancer therapy
*In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for CLL and CML by line of therapy and disease stage
*Ranking of key prescribing influences in CLL and CML, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview
Highlights
Rituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo) has received considerable off-label use for chronic lymphocytic leukemia (CLL), particularly in the US. Positive Phase III data are likely to drive increased uptake in the EU. Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering).
Gleevec is firmly established as the standard-of-care for newly diagnosed chronic phase CML, while the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) are experiencing increasing uptake in Gleevec-resistant and accelerated phase patients.
Sprycel currently commands a higher market share than Tasigna for CML, benefiting from its first-to-market advantage. However, physicians' perceptions of Sprycel and Tasigna show little differentiation, and there will be close competition for market share in the coming years.
Reasons to Purchase
*Understand prescribing trends and identify key factors that influence treatment choices in CLL and CML
*Examine unmet need within the CLL and CML markets and identify opportunities for new product development
*Enhance commercial positioning by increasing understanding of current dynamics within the CLL and CML markets
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
